Compared with MB-NHL, TP53 (75% vs. 54%) and ARID1A (35% vs. 7%) showed a higher incidence of mutation than IR MB-NHL (Fig. 1a and c), with the incidence of ARID1A mutation reaching a significant difference (P = 0.006, Fig. 1d). This evidence concerns the gene TP53 and non-Hodgkin lymphoma.